Download PDF
Psychiatr Prax 2013; 40(07): 380-384
DOI: 10.1055/s-0033-1343185
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Antipsychotische Polypharmazie bei Patienten mit Schizophrenie und hoher Versorgungsinanspruchnahme

Antipsychotic Polypharmacy in High-Utilising Patients with Schizophrenia
Christian Schmidt-Kraepelin
1   LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf
,
Bernd Puschner
2   Klinik für Psychiatrie und Psychotherapie II, Sektion Prozess-Ergebnisforschung, Universität Ulm
,
Sabine Loos
2   Klinik für Psychiatrie und Psychotherapie II, Sektion Prozess-Ergebnisforschung, Universität Ulm
,
Birgit Janssen
1   LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
16 May 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Anliegen: Antipsychotische Polypharmazie wird häufig bei Patienten mit Schizophrenie eingesetzt obwohl klinische Behandlungsleitlinien in der Regel hiervon abraten.

Methode: Die Anzahl der verordneten Antipsychotika wurde anhand einer repräsentativen Stichprobe von 2 unabhängigen Multizenterstudien an 638 Patienten erhoben.

Ergebnis: Mehrfachkombinationsbehandlungen wurden bei 43,9 % der Patienten angewendet, solche ohne Clozapin bei 36,2 %.

Schlussfolgerung: Die Ergebnisse weisen auf eine gängige Verordnungspraxis antipsychotischer Kombinationsbehandlungen auch ohne den Einsatz von Clozapin hin, die durch Therapierefraktärität und das Behandlungssetting beeinflusst sein könnten.

Abstract

Objectives: Although guidelines usually recommend monotherapy, in clinical practice, antipsychotic polypharmacy is common especially with chronically ill patients. We therefore assessed the current practice of antipsychotic polypharmacy in “high-utilising” patients with schizophrenia in Germany.

Methods: Antipsychotic medication was assessed using a representative sample of 638 patients with schizophrenia from two multi-centre studies.

Results: Antipsychotic combination treatment was administered to 43.9 % of the patients. Combination treatment not including clozapine was apparent in 36.2 %.

Conclusions: Antipsychotic polypharmacy is prevalent in the treatment of patients with schizophrenia showing high service use also when excluding such combinations with clozapine. Differences between the study samples indicate possible influences linked with therapy resistance or treatment setting.

Schlüsselwörter

Schizophrenie - Antipsychotika - Polypharmazie - Kombinationsbehandlung - hohe Versorgungsinanspruchnahme

Keywords

schizophrenia - antipsychotic - polypharmacy - combination treatment - high utilising patients
 

  • Literatur

  • 1 Correll CU, Rummel-Kluge C, Corves C et al. Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull 2009; 35: 443-457
    Search in Google Scholar
  • 2 Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry 2004; 11: 313-327
    CrossrefPubMedSearch in Google Scholar
  • 3 Messer T, Schmauß M. Polypharmazie in der Behandlung psychischer Erkrankungen. Wien, New York: Springer; 2006
    Search in Google Scholar
  • 4 Oepen G. Polypharmacy in Schizophrenia. In: Ghaemi NS, eds. Polypharmacy in Psychiatry. 1st. Edition. New York: Marcel Dekker Inc; 2002: 101-132
    CrossrefSearch in Google Scholar
  • 5 Schroeder NH, Caffey EM, Lorei TW. Antipsychotic drug use: Physician prescribing practices in relation to current recommendations. Dis Nerv Syst 1977; 38: 114-116
    PubMedSearch in Google Scholar
  • 6 Faries D, Ascher-Svanum H, Zhu B et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005; 5: 26
    CrossrefPubMedSearch in Google Scholar
  • 7 Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323-330
    CrossrefPubMedSearch in Google Scholar
  • 8 Tranulis C, Skalli L, Lalonde P et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safety 2008; 31: 7-20
    CrossrefPubMedSearch in Google Scholar
  • 9 Citrome L, Jaffe A, Levine J et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004; 55: 1006-1013
    CrossrefPubMedSearch in Google Scholar
  • 10 Joukamaa M, Heliövaara M, Knekt P et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-127
    CrossrefPubMedSearch in Google Scholar
  • 11 Puschner B, Steffen S, Gaebel W et al. Needs-oriented discharge planning and monitoring for high utilisers of psychiatric services (NODPAM): design and methods. BMC Health Serv Res 2008; 8: 152
    CrossrefPubMedSearch in Google Scholar
  • 12 Endicott J, Spitzer RL, Fleiss JL et al. The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance. Arch Gen Psychiatry 1976; 33: 766-771
    Search in Google Scholar
  • 13 Chisholm D, Knapp MR, Knudsen HC et al. Client Socio-Demographic and Service Receipt Inventory-European Version: development of an instrument for international research. Br J Psychiatry 2000; 39 (Suppl. 01) 28-33
    PubMedSearch in Google Scholar
  • 14 Rittmannsberger H. The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 547-551
    CrossrefPubMedSearch in Google Scholar
  • 15 Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987; 150: 501-504
    CrossrefPubMedSearch in Google Scholar